These prima vista contradictory results leave room for additional investigations, particularly the regulative role of Trx1 on HIF-2α is an attractive target with respect to the current phase III clinical trials that investigate HIF-2α inhibition as a therapeutic concept in ccRCC and other cancer types. Here, TXN is linked to cancer.